Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?

Targeted therapeutics underwent a revolution with the entry of monoclonal antibodies in the medical toolkit. Oligonucleotide aptamers form another family of target agents that have been lagging behind in reaching the clinical arena in spite of their potential clinical translation. Some of the reason...

Descripción completa

Detalles Bibliográficos
Autores principales: Sola, Mayte, Menon, Ashwathi Puravankara, Moreno, Beatriz, Meraviglia-Crivelli, Daniel, Soldevilla, Mario Martínez, Cartón-García, Fernando, Pastor, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321788/
https://www.ncbi.nlm.nih.gov/pubmed/32585627
http://dx.doi.org/10.1016/j.omtn.2020.05.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321788/
https://www.ncbi.nlm.nih.gov/pubmed/32585627
http://dx.doi.org/10.1016/j.omtn.2020.05.025

Ejemplares similares